FRA:MRK - Merck KGaA Stock Price, News, & Analysis

Get Started

€97.64 +4.14 (+4.43 %)

(As of 11/18/2018 01:41 AM ET)

Previous Close€97.64

Today's Range€95.90 - €98.10

52-Week Range€76.60 - €115.00

Volume779,281 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange FRA

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolFRA:MRK

Previous Symbol

CUSIPN/A

Webwww.merckgroup.com

Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees54,009

Outstanding SharesN/A

Market Cap$0.00

OptionableOptionable

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

20 Wall Street analysts have issued 1-year price targets for Merck KGaA's stock. Their forecasts range from €72.00 to €115.00. On average, they anticipate Merck KGaA's share price to reach €98.00 in the next year. This suggests a possible upside of 0.4% from the stock's current price. View Analyst Price Targets for Merck KGaA.

What is the consensus analysts' recommendation for Merck KGaA?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 2 sell ratings, 11 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

Headlines about MRK stock have trended neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck KGaA earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the healthcare company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), Cipher Pharmaceuticals (CPH) and Cosmos (COSM).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 61)
Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 50)
Dr. Walter Galinat, Member of Exec. Board (Age 62)
Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 53)
Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 47)

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €97.64.

What is Merck KGaA's official website?

The official website for Merck KGaA is https://www.merckgroup.com/.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.

MarketBeat Community Rating for Merck KGaA (FRA MRK)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		711 (Vote Outperform)
Underperform Votes:		782 (Vote Underperform)
Total Votes:		1,493

MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 11/18/2018 by MarketBeat.com Staff

Featured Article: How Does the Quiet Period Work?